Alvogen Korea failed to cross the last hurdle in the Roche anticancer drug Avastin patent challenge. It challenged three patents, but succeeded in overcoming only two and failed one.

The Korean Intellectual Property Tribunal recently dismissed the Avastin patent invalidation trial filed by Alvogen Korea against Roche. As a result, the original company Roche succeeded in defending one out of three related patents in the first trial. Roche has registered a total of four patents in Avastin. It is one patent for substance and three patents for use. One patent for substances registered in Korea has already expired in April 2018.

In August last year, Alvogen filed a series of invalidation trial